Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Foundation Fighting Blindness has granted $1.5m grant to Applied Genetic Technologies to support its pre-clinical trial investigating the safety and efficacy of a gene therapy treatment for X-linked Retinoschisis (XLRS).
Subscribe to our email newsletter
The work is being coordinated by AGTC under an agreement with researchers at Oregon Health & Science University Casey Eye Institute, David Wilson and The University of Florida, William Hauswirth.
AGTC president and CEO Sue Washer said this funding will enable them to finish final testing of the treatment in animal models of XLRS as well as complete the pre-clinical safety studies required by the FDA in order to start a Phase 1 human clinical trial.